The stock of Cidara Therapeutics Inc (NASDAQ:CDTX) is a huge mover today! About 196,054 shares traded hands or 281.09% up from the average. Cidara Therapeutics Inc (NASDAQ:CDTX) has risen 13.81% since March 4, 2016 and is uptrending. It has outperformed by 5.77% the S&P500.
The move comes after 6 months negative chart setup for the $139.75 million company. It was reported on Oct, 7 by Barchart.com. We have $9.08 PT which if reached, will make NASDAQ:CDTX worth $15.37M less.
Analysts await Cidara Therapeutics Inc (NASDAQ:CDTX) to report earnings on November, 21. They expect $-0.80 earnings per share, down 19.40% or $0.13 from last year’s $-0.67 per share. After $-0.85 actual earnings per share reported by Cidara Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
According to Zacks Investment Research, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.”
More notable recent Cidara Therapeutics Inc (NASDAQ:CDTX) news were published by: Globenewswire.com which released: “Cidara Therapeutics Expands Management Team” on July 05, 2016, also Globenewswire.com with their article: “Cidara Therapeutics Announces Pricing of Initial Public Offering” published on April 15, 2015, Globenewswire.com published: “Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of …” on November 16, 2015. More interesting news about Cidara Therapeutics Inc (NASDAQ:CDTX) were released by: Businesswire.com and their article: “Cidara Therapeutics to Present Data from Antifungal Drug Development Programs …” published on August 10, 2015 as well as Fiercebiotech.com‘s news article titled: “Cidara Therapeutics – 2014 Fierce 15” with publication date: September 22, 2014.
CDTX Company Profile
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., incorporated on December 06, 2012, is a clinical-stage biotechnology company. The Firm is engaged in the discovery, development and commercialization of anti-infectives. The Firm is developing a pipeline of product and development candidates, with a focus on serious fungal infections. The Company’s lead clinical candidates are echinocandins, a class of antifungals. The Company’s product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, it has developed an immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. It is evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal pathogen, Aspergillus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.